Drug-induced interstitial lung disease

Excerpt

Antineoplastics, antirheumatics and cardiovascular therapies are the drug classes most likely to cause drug-induced interstitial lung disease (DILD), according to findings of a retrospective study published in Therapeutic Advances in Drug Safety .Disproportionality analysis of data from the US FDA Adverse Event Reporting System (FAERS) from 2004 to 2021 was used to evaluate which drugs were most frequently associated with DILD.In total, data from 25 501 reports of DILD in the FAERS database were analysed. The number of reports per year increased from approximately 700 to 3645 by 2020.The drug classes most frequently reported in cases of DILD were antineoplastics (48%), cardiovascular therapies (11%) and antirheumatics (10%), but the order differed between sexes and between countries.The drugs with the strongest association with DILD were trastuzumab deruxtecan (reporting odds ratio [ROR] 56.50), ramucirumab (ROR 36.28) and eribulin (ROR 30.57). Of note, labelling for half of the 20 drugs most strongly associated with DILD, including amiodarone, doxorubicin, temsirolimus and ursodiol, did not mention DILD."In a review of the FAERS database, we uncovered that the top drug classes associated with DILD in FAERS were antineoplastic, cardiovascular, and antirheumatic agents, in varying order in different sexes/age . . . We also found some unexpected drugs without DILD in the labels, such as amiodarone, doxorubicin, and ursodiol," the authors concluded. …